Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics

P. Todd Korthuis, Mary Jo Tozzi, Vijay Nandi, David A. Fiellin, Linda Weiss, James E. Egan, Michael Botsko, Angela Acosta, Marc Gourevitch, David Hersh, Jeffrey Hsu, Joshua Boverman, Frederick L. Altice

Research output: Contribution to journalArticle

Abstract

Background: Opioid dependence and HIV infection are associated with poor health-related quality of life (HRQOL). Buprenorphine/naloxone (bup/nx) provided in HIV care settings may improve HRQOL. Methods: We surveyed 289 HIV-infected opioid-dependent persons treated with clinic-based bup/nx about HRQOL using the Short Form Health Survey (SF-12) administered at baseline, 3, 6, 9, and 12 months. We used normalized SF-12 scores, which correspond to a mean HRQOL of 50 for the general US population (SD 10, possible range 0-100). We compared mean normalized mental and physical composite and component scores in quarters 1, 2, 3, and 4 with baseline scores using generalized estimating equation models. We assessed the effect of clinic-based bup/nx prescription on HRQOL composite scores using mixed effects regression with site as random effect and time as repeated effect. Results: Baseline normalized SF-12 scores were lower than the general US population for all HRQOL domains. Average composite mental HRQOL improved from 38.3 (SE 12.5) to 43.4 (SE 13.2) [β 1.13 (95% CI: 0.72 to 1.54)] and composite physical HRQOL remained unchanged [β 0.21 (95% CI: -0.16 to 0.57)] over 12 months follow-up. Continued bup/nx treatment across all 4 quarters was associated with improvements in both physical [β 2.38 (95% CI: 0.63 to 4.12)] and mental [β 2.51 (95% CI: 0.42 to 4.60)] HRQOL after adjusting for other contributors to HRQOL. Conclusions: Clinic-based bup/nx maintenance therapy is potentially effective in ameliorating some of the adverse effects of opioid dependence on HRQOL for HIV-infected populations.

Original languageEnglish (US)
JournalJournal of Acquired Immune Deficiency Syndromes
Volume56
Issue numberSUPPL. 1
DOIs
StatePublished - Mar 1 2011

Fingerprint

Buprenorphine
Opioid Analgesics
Quality of Life
HIV
Therapeutics
Population
Health Surveys
HIV Infections
Prescriptions
Mental Health
Naloxone Drug Combination Buprenorphine

Keywords

  • buprenorphine
  • HIV infections
  • intravenous
  • opioidrelated disorders
  • quality of life
  • substance abuse

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics. / Korthuis, P. Todd; Tozzi, Mary Jo; Nandi, Vijay; Fiellin, David A.; Weiss, Linda; Egan, James E.; Botsko, Michael; Acosta, Angela; Gourevitch, Marc; Hersh, David; Hsu, Jeffrey; Boverman, Joshua; Altice, Frederick L.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 56, No. SUPPL. 1, 01.03.2011.

Research output: Contribution to journalArticle

Korthuis, PT, Tozzi, MJ, Nandi, V, Fiellin, DA, Weiss, L, Egan, JE, Botsko, M, Acosta, A, Gourevitch, M, Hersh, D, Hsu, J, Boverman, J & Altice, FL 2011, 'Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics', Journal of Acquired Immune Deficiency Syndromes, vol. 56, no. SUPPL. 1. https://doi.org/10.1097/QAI.0b013e318209754c
Korthuis, P. Todd ; Tozzi, Mary Jo ; Nandi, Vijay ; Fiellin, David A. ; Weiss, Linda ; Egan, James E. ; Botsko, Michael ; Acosta, Angela ; Gourevitch, Marc ; Hersh, David ; Hsu, Jeffrey ; Boverman, Joshua ; Altice, Frederick L. / Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics. In: Journal of Acquired Immune Deficiency Syndromes. 2011 ; Vol. 56, No. SUPPL. 1.
@article{9334b1be9f88448ab6b2339520c52196,
title = "Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics",
abstract = "Background: Opioid dependence and HIV infection are associated with poor health-related quality of life (HRQOL). Buprenorphine/naloxone (bup/nx) provided in HIV care settings may improve HRQOL. Methods: We surveyed 289 HIV-infected opioid-dependent persons treated with clinic-based bup/nx about HRQOL using the Short Form Health Survey (SF-12) administered at baseline, 3, 6, 9, and 12 months. We used normalized SF-12 scores, which correspond to a mean HRQOL of 50 for the general US population (SD 10, possible range 0-100). We compared mean normalized mental and physical composite and component scores in quarters 1, 2, 3, and 4 with baseline scores using generalized estimating equation models. We assessed the effect of clinic-based bup/nx prescription on HRQOL composite scores using mixed effects regression with site as random effect and time as repeated effect. Results: Baseline normalized SF-12 scores were lower than the general US population for all HRQOL domains. Average composite mental HRQOL improved from 38.3 (SE 12.5) to 43.4 (SE 13.2) [β 1.13 (95{\%} CI: 0.72 to 1.54)] and composite physical HRQOL remained unchanged [β 0.21 (95{\%} CI: -0.16 to 0.57)] over 12 months follow-up. Continued bup/nx treatment across all 4 quarters was associated with improvements in both physical [β 2.38 (95{\%} CI: 0.63 to 4.12)] and mental [β 2.51 (95{\%} CI: 0.42 to 4.60)] HRQOL after adjusting for other contributors to HRQOL. Conclusions: Clinic-based bup/nx maintenance therapy is potentially effective in ameliorating some of the adverse effects of opioid dependence on HRQOL for HIV-infected populations.",
keywords = "buprenorphine, HIV infections, intravenous, opioidrelated disorders, quality of life, substance abuse",
author = "Korthuis, {P. Todd} and Tozzi, {Mary Jo} and Vijay Nandi and Fiellin, {David A.} and Linda Weiss and Egan, {James E.} and Michael Botsko and Angela Acosta and Marc Gourevitch and David Hersh and Jeffrey Hsu and Joshua Boverman and Altice, {Frederick L.}",
year = "2011",
month = "3",
day = "1",
doi = "10.1097/QAI.0b013e318209754c",
language = "English (US)",
volume = "56",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics

AU - Korthuis, P. Todd

AU - Tozzi, Mary Jo

AU - Nandi, Vijay

AU - Fiellin, David A.

AU - Weiss, Linda

AU - Egan, James E.

AU - Botsko, Michael

AU - Acosta, Angela

AU - Gourevitch, Marc

AU - Hersh, David

AU - Hsu, Jeffrey

AU - Boverman, Joshua

AU - Altice, Frederick L.

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Background: Opioid dependence and HIV infection are associated with poor health-related quality of life (HRQOL). Buprenorphine/naloxone (bup/nx) provided in HIV care settings may improve HRQOL. Methods: We surveyed 289 HIV-infected opioid-dependent persons treated with clinic-based bup/nx about HRQOL using the Short Form Health Survey (SF-12) administered at baseline, 3, 6, 9, and 12 months. We used normalized SF-12 scores, which correspond to a mean HRQOL of 50 for the general US population (SD 10, possible range 0-100). We compared mean normalized mental and physical composite and component scores in quarters 1, 2, 3, and 4 with baseline scores using generalized estimating equation models. We assessed the effect of clinic-based bup/nx prescription on HRQOL composite scores using mixed effects regression with site as random effect and time as repeated effect. Results: Baseline normalized SF-12 scores were lower than the general US population for all HRQOL domains. Average composite mental HRQOL improved from 38.3 (SE 12.5) to 43.4 (SE 13.2) [β 1.13 (95% CI: 0.72 to 1.54)] and composite physical HRQOL remained unchanged [β 0.21 (95% CI: -0.16 to 0.57)] over 12 months follow-up. Continued bup/nx treatment across all 4 quarters was associated with improvements in both physical [β 2.38 (95% CI: 0.63 to 4.12)] and mental [β 2.51 (95% CI: 0.42 to 4.60)] HRQOL after adjusting for other contributors to HRQOL. Conclusions: Clinic-based bup/nx maintenance therapy is potentially effective in ameliorating some of the adverse effects of opioid dependence on HRQOL for HIV-infected populations.

AB - Background: Opioid dependence and HIV infection are associated with poor health-related quality of life (HRQOL). Buprenorphine/naloxone (bup/nx) provided in HIV care settings may improve HRQOL. Methods: We surveyed 289 HIV-infected opioid-dependent persons treated with clinic-based bup/nx about HRQOL using the Short Form Health Survey (SF-12) administered at baseline, 3, 6, 9, and 12 months. We used normalized SF-12 scores, which correspond to a mean HRQOL of 50 for the general US population (SD 10, possible range 0-100). We compared mean normalized mental and physical composite and component scores in quarters 1, 2, 3, and 4 with baseline scores using generalized estimating equation models. We assessed the effect of clinic-based bup/nx prescription on HRQOL composite scores using mixed effects regression with site as random effect and time as repeated effect. Results: Baseline normalized SF-12 scores were lower than the general US population for all HRQOL domains. Average composite mental HRQOL improved from 38.3 (SE 12.5) to 43.4 (SE 13.2) [β 1.13 (95% CI: 0.72 to 1.54)] and composite physical HRQOL remained unchanged [β 0.21 (95% CI: -0.16 to 0.57)] over 12 months follow-up. Continued bup/nx treatment across all 4 quarters was associated with improvements in both physical [β 2.38 (95% CI: 0.63 to 4.12)] and mental [β 2.51 (95% CI: 0.42 to 4.60)] HRQOL after adjusting for other contributors to HRQOL. Conclusions: Clinic-based bup/nx maintenance therapy is potentially effective in ameliorating some of the adverse effects of opioid dependence on HRQOL for HIV-infected populations.

KW - buprenorphine

KW - HIV infections

KW - intravenous

KW - opioidrelated disorders

KW - quality of life

KW - substance abuse

UR - http://www.scopus.com/inward/record.url?scp=79951777614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951777614&partnerID=8YFLogxK

U2 - 10.1097/QAI.0b013e318209754c

DO - 10.1097/QAI.0b013e318209754c

M3 - Article

C2 - 21317593

AN - SCOPUS:79951777614

VL - 56

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - SUPPL. 1

ER -